Compare Enveric Biosciences Inc (ENVB) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $7.00B). The key difference: Invesco S&P 500 Low Volatility ETF is far larger — about 1046.3× Enveric Biosciences Inc's market cap, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| ENVB | SPLV | |
|---|---|---|
Market Cap | $6.69M | $7.00B |
Volume | 41,141 | 1,622,563 |
Sector | Health | — |
52-Week High | $10.80 | $77.97 |
52-Week Low | $1.27 | $70.30 |
Typical Hold Time | 14 Days | 123 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SPLV trades at $71.22, down 0.71% with a bearish technical signal from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 per share were distributed in July and September 2026, while technical indicators show mixed signals with neutral RSI readings but strong bearish ADX momentum.
The outlook remains challenged by sector headwinds and unappealing growth-adjusted valuation at 19.5x P/E. Key risks include continued underperformance relative to broader market and sensitivity to interest rate movements. Opportunities exist for investors seeking low-volatility exposure during market uncertainty, though near-term catalysts appear limited.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
